2024/07/16 17:35:12 | |
---|---|
Price | |
0.2675 EUR | |
Difference | -0.37% (-0.00) |
ISIN | BE0974260896 |
Symbol | CYAD |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 11 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.25 EUR |
High | 0.268 EUR |
Low | 0.25 EUR |
Close (prev. day) | 0.2685 EUR |
VWAP | 0.25589 EUR |
Volume (pcs) | 11,758 |
Trading volume | 3,009.00 |
Number of trades | 20 |
Last size | 195 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/16 17:35:12 | |
---|---|
Price | |
0.2675 EUR | |
Difference | -0.37% (-0.00) |
ISIN | BE0974260896 |
Symbol | CYAD |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 11 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.25 EUR |
High | 0.268 EUR |
Low | 0.25 EUR |
Close (prev. day) | 0.2685 EUR |
VWAP | 0.25589 EUR |
Volume (pcs) | 11,758 |
Trading volume | 3,009.00 |
Number of trades | 20 |
Last size | 195 |
6m | 1Y | 3Y | |
Perf (%) | -27.11% | -50.65% | -92.57% |
Perf (abs.) | -0.10 | -0.27 | -3.33 |
Beta | 0.42 | 0.28 | 0.59 |
Volatility | 59.06 | 88.22 | 89.57 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.2650 EUR (11,701) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.2868 EUR (14,326) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.3207 EUR (14,432) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.4479 EUR (33,575) |
YTD High | date | 0.4700 EUR (2024/01/26) |
YTD Low | date | 0.2310 EUR (2024/07/01) |
52 Weeks High | date | 1.2800 EUR (2023/09/04) |
52 Weeks Low | date | 0.2310 EUR (2024/07/01) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2024/07/16 | 13:33 | 0.242 EUR | 0.00 | 4 |
Munich | 2024/07/16 | 08:08 | 0.299 EUR | 0.00 | 1 |
London Stock Exchange | 2021/01/27 | 09:06 | 6.9303 EUR | 0.00 | 1 |
Frankfurt | 2024/07/16 | 08:02 | 0.2285 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/07/08 | 18:39 | 0.25 USD | 0.00 | 1 |
Euronext Brussels | 2024/07/16 | 17:35 | 0.2675 EUR | 0.00 | 20 |
Duesseldorf | 2024/07/16 | 08:10 | 0.239 EUR | 0.00 | 3 |
Berlin | 2024/07/16 | 08:08 | 0.2285 EUR | 0.00 | 3 |
CELYAD ONCOLOGY SA |
- - |
Axis Business Park, Rue André Dumont 9 - 1435 Mont-Saint-Guibert |
Telefon: +32-10-039-41-00 |
Fax: +32-10-039-41-41 |
E-mail: info@celyad.com |
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. |
Georges Rawadi | Chairman of Managing Board |
An Phan | Member of Executive Committee |
David Georges | Member of Executive Committee |
Eytan Breman | Member of Executive Committee |
Hannes Iserentant | Member of Executive Committee |
Hilde Windels | Chairman of Supervisory Board |
Marina Udier | Member of Supervisory Board |
Ami Shah | Member of Supervisory Board |
Andrea Gothing | Member of Supervisory Board |
Dominic Piscitelli | Member of Supervisory Board |
John LiPuma | Member of Supervisory Board |
Jonathan James | Member of Supervisory Board |
Sage Mandel | Member of Supervisory Board |
Serge Goblet | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer